Scarica l'app Stockscreener
8.21
0.85%
-0.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NXTC Giù?
Forum
Previsione
Nextcure Inc Borsa (NXTC) Ultime notizie
Ikarian Capital discloses 9.99% NextCure (NXTC) stake including large warrant position - Stock Titan
NextCure (NXTC) gains 15.8% beneficial owner in ADAR1 Capital and manager - Stock Titan
NextCure Inc (NASDAQ: NXTC) Stock Price, News & Analysis - Kalkine
NextCure (NXTC): Squadron funds and partners disclose 1.6% equity stake - Stock Titan
Affinity Asset Advisors discloses 6.4% NextCure (NXTC) stake via stock and warrants - Stock Titan
NextCure stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Major Former Stakeholder Makes a Significant Move in NextCure Stock - TipRanks
Adage Capital files Schedule 13G showing 7.67% NextCure (NXTC) ownership - Stock Titan
Simcere Zaiming sells $184,800 of NextCure stock - Investing.com
Simcere Zaiming sells $184,800 of NextCure stock By Investing.com - Investing.com Canada
Simcere group (NXTC) trims NextCure stake, ends 10% beneficial ownership - Stock Titan
RTW Biotech's Avere to go public in US in reverse merger with NextCure - London South East
NextCure - thepharmaletter.com
NextCure (NXTC) plans reverse merger with Avere and $820M financings - Stock Titan
Xcellon Acquires 40,000 Sq ft Maryland Facility from NextCure to Deliver a cGMP-Ready CRDMO for ADCs - BioBuzz
Xcellon Biologics Acquires GMP Manufacturing Facility from NextCure, Becoming an End-to-End CRDMO for Next-Generation Bioconjugates and Complex Biologics - The Manila Times
Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001 - Nasdaq
NextCure Inc (NXTC) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
NextCure reports Q2 2026 net loss $14.9M, cash $20.1M as it pursues merger with Avere - TradingView
NextCure, Inc. Q2 2026: Net income $(14.9)M, EPS $(2.80) — 10-Q Summary - TradingView
NextCure (NASDAQ: NXTC) details Avere merger, $320M financing and going concern risk - Stock Titan
NextCure (Nasdaq: NXTC) details Q2 2026 loss and Avere merger - Stock Titan
NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results - The Manila Times
NextCure Q2 FY26 net loss narrows to $14.89 million; R&D expenses drop to $7.43 million - Bitget
NextCure (NXTC) details two-step Avere merger plan and upcoming Form S-4 - Stock Titan
Form 4 NextCure Inc For: 4 August By Investing.com - Investing.com UK
Adar1 Capital Management buys $1.6m in NextCure (NXTC) shares - Investing.com
Adar1 Capital Management buys $1.6m in NextCure (NXTC) shares By Investing.com - Investing.com India
ADAR1 Capital Management reports NextCure common share purchase worth $3.59 million - Bitget
ADAR1-managed funds buy 329,153 shares of NextCure (NXTC) - Stock Titan
NextCure Inc expected to post a loss of $1.93 a shareEarnings Preview - TradingView
NextCure, Inc. Revenue Breakdown – NASDAQ:NXTC - TradingView
Form 4 NextCure Inc For: 29 July By Investing.com - Investing.com South Africa
Adar1 capital management increases NextCure (NXTC) stake by $87,712 - Investing.com Canada
NXTC|NextCure Inc|Price:5.200|Chg%:+0.960 - TradingKey
NextCure Inc (NXTC) Cash Flow - TradingKey
NextCure Inc (NXTC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NextCure Inc (NXTC) Balance Sheet - TradingKey
NextCure Inc (NXTC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NextCure Inc (NXTC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NXTC|NextCure Inc|Price:5.090|Chg%:+0.850 - TradingKey
NextCure Inc (NXTC) Income Statement - TradingKey
NextCure, Inc. Revenue Breakdown – MUN:2US0 - TradingView
NextCure Inc. (NXTC) Edges Higher as Biotech Sentiment Shifts — Resistance Test LoomsLong Term Entry Picks - dars.gov.et
NextCure Inc (NXTC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Gibson Dunn guides biotech reverse merger - ICLG
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--VEEE, NXTC, TCBK, and FHB - Finansavisen
NextCure Inc. (NXTC) Q1 2026 Earnings: EPS Beats Estimates, Stock Declines on Pre-Revenue StatusROIC Trend Report - dars.gov.et
Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders? - Finansavisen
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—VEEE, NXTC, TCBX, and FHB - Carroll County Mirror-Democrat
NextCure announces reverse merger with privately held Avere - MSN
Hansoh takes newco route to globalize IL-23 asset - BioWorld News
Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders - GlobeNewswire
Sidley Represents NextCure in Merger With Avere Therapeutics and Concurrent US$320 Million Private Placement - Legal Desire Media and Insights
NextCure Inc. (NXTC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
NextCure Inc. (NXTC) Faces Continued Pressure, Testing Key Support LevelsElliott Wave Entry - dars.gov.et
NextCure and Avere Therapeutics Announce Merger and $320 Million Private Financing - Global Legal Chronicle
NextCure (NASDAQ: NXTC) details Avere merger structure and S-4 plan - Stock Titan
Nextcure transforms into Avere as investors back oral psoriasis therapy - MSN
NextCure Announces Transformative All-Stock Merger With Avere - The Globe and Mail
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):